new weight loss injection retatrutide Results:Trial Data and FDA Status Unapproved weight loss drug retatrutide

The increased risk of PD in postmenopausal women indicates that estrogen (E2) has neuroprotective effects [187, 188]

Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the asia-pacific region: the SURPASS-AP-combo trial

Key industry players Novo Nordisk, Eli Lilly, AstraZeneca and Sanofi lead the charge in GLP-1 drugs

high pharmacologic doses (1-3 g/day) can cause hypotension, insulin resistance, and hepatotoxicity

Most patients experience some side effects, but the difference between a manageable adjustment period and a miserable one is rarely about the drug itself

This process is characterized by permanent cell cycle arrest and is associated with aging, tissue degeneration, and various diseases, including cancer